Advances in Cardiology in 2023
Main Article Content
Abstract
Cardiology continues to evolve from year to year with major advances in its different disciplines which we have summarized in this review by selecting the main chapters allowing us to improve our daily practice.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392:1736–88. https://doi.org/10.1016/s0140-6736(18)32203-7
II. Montalescot G, van’t Hof AW, Lapostolle F, Silvain J, Lassen JF, Bolognese L, et al. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med 2014;371:1016–27. https://doi.org/10.1056/NEJMoa1407024
III. Schüpke S, Neumann FJ, Menichelli M, Mayer K, Bernlochner I, Wöhrle J, et al. Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med 2019;381:1524–34. https://doi.org/10.1056/NEJMoa1908973
IV. Kamran H, Jneid H, Kayani WT, Virani SS, Levine GN, Nambi V, Khalid U. Oral Antiplatelet Therapy After Acute Coronary Syndrome: A Review. JAMA. 2021 Apr 20;325(15):1545-55. doi: 10.1001/jama.2021.0716. Erratum in: JAMA. 2021 Jul 13;326(2):190. PMID: 33877270.
V. Valgimigli M, Smits PC, Frigoli E, Bongiovanni D, Tijssen J, Hovasse T, Mafragi A, Ruifrok WT, Karageorgiev D, Aminian A, Garducci S, Merkely B, Routledge H, Ando K, Diaz Fernandez JF, Cuisset T, Nesa Malik FT, Halabi M, Belle L, Din J, Beygui F, Abhyankar A, Reczuch K, Pedrazzini G, Heg D, Vranckx P; MASTER DAPT Investigators. Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysis. Eur Heart J. 2022 Sep 1;43(33):3100-14. doi: 10.1093/eurheartj/ehac284. PMID: 35580836.
VI. TW, Räber L, di Mario C, Bourantas C, Jia H, Mattesini A, et al. Clinical use of intracoronary imaging. Part 2: acute coronary syndromes, ambiguous coronary angiography findings, and guiding interventional decision-making: an expert consensus document of the European Association of Percutaneous Cardiovascular Interventions. Eur Heart J 2019;40:2566–84.
https://doi.org/10.1093/eurheartj/ehz332
VII. Secemsky EA, Butala N, Raja A, Khera R, Wang Y, Curtis JP, et al. Temporal changes and institutional variation in use of percutaneous coronary intervention for ST-elevation myocardial infarction with multivessel coronary artery disease in the United States: an NCDR research to practice project. JAMA Cardiol 2021;6:574–80. https://doi.org/10.1001/jamacardio.2020.5354.
VIII. Bainey KR, Engstrøm T, Smits PC, Gershlick AH, James SK, Storey RF, et al. Complete vs culprit-lesion-only revascularization for ST-segment elevation myocardial infarction: a systematic review and meta-analysis. JAMA Cardiol 2020;5:881–88. https://doi.org/10.1001/jamacardio.2020.1251
IX. Eggers KM, James SK, Jernberg T, Lindahl B. Timing of coronary angiography in patients with non-ST-elevation acute coronary syndrome: long-term clinical outcomes from the nationwide SWEDEHEART registry. EuroIntervention 2022;18:582–89. https://doi.org/10.4244/eij-d-21-00982
X. Velders MA, Boden H, Hofma SH, Osanto S, van der Hoeven BL, Heestermans AACM, et al. Outcome after ST elevation myocardial infarction in patients with cancer treated with primary percutaneous coronary intervention. Am J Cardiol 2013;112:1867–72. https://doi.org/10.1016/j.amjcard.2013.08.019
XI. Long M, Ye Z, Zheng J, Chen W, Li L. Dual anti-platelet therapy following percutaneous coronary intervention in a population of patients with thrombocytopenia at baseline: a meta-analysis. BMC Pharmacol Toxicol 2020;21:31. https://doi.org/10.1186/s40360-020-00409-2
XII. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2017;38:2459–72.
https://doi.org/10.1093/eurheartj/ehx144
XIII. Iannuzzo G, Gentile M, Bresciani A, Mallardo V, Di Lorenzo A, Merone P, et al. Inhibitors of protein convertase subtilisin/kexin 9 (PCSK9) and acute coronary syndrome (ACS): the state-of-the-art. J Clin Med 2021;10:1510.
https://doi.org/10.3390/jcm10071510
XIV. Nawabi AQ, Hassan W, Chen L, Shaikh N, Abbas K, Zehra FT. Is Colchicine a New Game-Changer in Patients With Acute Coronary Syndrome? Cureus. 2022 Mar 5;14(3):e22874.
doi: 10.7759/cureus.22874.
XV. Taleb S. Inflammation in atherosclerosis. Arch Cardiovasc Dis. 2016 Dec;109(12):708-15. doi: 10.1016/j.acvd.2016.04.002. Epub 2016 Aug 29.
XVI. Akrami M, Izadpanah P, Bazrafshan M, Hatamipour U, Nouraein N, Drissi HB, Manafi A. Effects of colchicine on major adverse cardiac events in next 6-month period after acute coronary syndrome occurrence; a randomized placebo-control trial. BMC Cardiovasc Disord. 2021 Dec 7;21(1):583. doi: 10.1186/s12872-021-02393-9. PMID: 34876021; PMCID: PMC8650300.
XVII. Opstal TSJ, Fiolet ATL, van Broekhoven A, Mosterd A, Eikelboom JW, Nidorf SM, Thompson PL, Duyvendak M, van Eck JWM, van Beek EA, den Hartog F, Budgeon CA, Bax WA, Tijssen JGP, El Messaoudi S, Cornel JH; LoDoCo2 Trial Investigators. Colchicine in Patients With Chronic Coronary Disease in Relation to Prior Acute Coronary Syndrome. J Am Coll Cardiol. 2021 Aug 31;78(9):859-66. doi: 10.1016/j.jacc.2021.06.037. PMID: 34446156.
XVIII. BOZKURT B, COATS AJS, TSUTUY H et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: endorsed by the Canadian Heat Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail, 2021;23:325-80.
XIX. DOCHERTY KF, JHUND PS, INZUCCHI SE et al. Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. Eur Heart J, 2020; 41:2379-92.
XX. VERMA S, DHRINGA NK, BUTLER J et al. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR Reduced): a post-hoc analysis of a randomized, double-blind trial. Lancet Diabetes Endocrinal, 2022 ; 10: 35-45.
XXI. 1. SOLOMON SD, VADUNAGATHAN M, CLAGGETT BL et al. Baseline characteristics of patients with HF with midly reduced and preserved ejection fraction. JACC Heart Fail, 2022;10:184-97.
XXII. SOLOMON SD, MCMURRAY JJV, CLAGGETT B et al. For the DELIVER trial Committees and Investigators. Dapagliflozin in heart failure with midly reduced or preserved ejection fraction. N Engl J Med, 2022;387:1089-98.
XXIII. Mebazaa A, Davison B, Chioncel O, Cohen-Solal A, Diaz R, Filippatos G, et al. Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial. Lancet 2022; 400:1938–52. https://doi.org/10.1016/S0140-6736(22)02076-1.
XXIV. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 2020; 383:2219–29. https://doi.org/10.1056/NEJMoa2025845.
XXV. Kalra PR, Cleland JGF, Petrie MC, Thomson EA, Kalra PA, Squire IB, et al. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet 2022;400:2199–209. https://doi.org/10.1016/S0140-6736(22)02083-9.
XXVI. Kosiborod MN, Abildstrøm SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023 Aug 25.
XXVII. Arbustini E,Narula N,Déc GW,Reddy KS,Greenberg B,Kushwaha S, et coll. La classification MOGE(S) pour une nomenclature phénotype-génotype de la cardiomyopathie : approuvée par la Fédération mondiale du cœur.J Am Coll Cardiol 2013;62:2046–72. https://doi.org/10.1016/j.jacc.2013.08.1644
XXVIII. Liu D, Hu K, Nordbeck P, Ertl G, Störk S, Weidemann F. Longitudinal strain bull’s eye plot patterns in patients with cardiomyopathy and concentric left ventricular hypertrophy. Eur J Med Res 2016;21:21. https://doi.org/10.1186/s40001-016-0216-y
XXIX. Rudolph A, Abdel-Aty H, Bohl S, Boye P, Zagrosek A, Dietz R, et al. Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy relation to remodeling. J Am Coll Cardiol 2009;53:284–91. https://doi.org/10.1016/j.jacc.2008.08.064
XXX. Norrlandais g,Ding T,Champ E,Žiolkowska L,Olivier I,Limongelli g, et coll. Développement d'un nouveau modèle de prédiction du risque de mort subite d'origine cardiaque dans les cardiomyopathies hypertrophiques infantiles (HCM Risk-Kids).JAMA Cardiol 2019;4:918–927. https://doi.org/10.1001/jamacardio.2019.2861
XXXI. Olivier je,Oréziak UN,Barriales-Villa R.,Abraham TP,Masri UN,Garcia-Pavie P., et coll. Mavacamten pour le traitement de la cardiomyopathie hypertrophique obstructive symptomatique (EXPLORER-HCM) : un essai de phase 3 randomisé, en double aveugle, contrôlé par placebo.Lancette 2020;396:759–69. https://doi.org/10.1016/S0140-6736(20)31792-X
XXXII. Stauffer JC,Ruiz V,Morard JD.Obstruction sous-aortique après sildénafil chez un patient atteint de cardiomyopathie hypertrophique.N Engl J Med 1999;341:700–01. https://doi.org/10.1056/NEJM199908263410916
XXXIII. Pinto YM, Elliott PM, Arbustini E, Adler Y, Anastasakis A, Bohm M, et al. Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J 2016;37:1850–58. https://doi.org/10.1093/eurheartj/ehv727
XXXIV. Pettersen MD, Du W, Skeens ME, Humes RA. Regression equations for calculation of z scores of cardiac structures in a large cohort of healthy infants, children, and adolescents: an echocardiographic study. J Am Soc Echocardiogr 2008;21:922–34. https://doi.org/10.1016/j.echo.2008.02.006
XXXV. Chubb H, Simpson JM. The use of Z-scores in paediatric cardiology. Ann Pediatr Cardiol 2012;5:179–84. https://doi.org/10.4103/0974-2069.99622
XXXVI. Seidel F,Holtgrewe M,Al-Wakeel-Marquard N,Opgen-Rhein B,Fléchettes J.,Herbst C, et coll. Les variantes pathogènes associées à la cardiomyopathie dilatée prédisent l'issue de la myocardite pédiatrique.Circ Genom Précis Med 2021;14:e003250.
XXXVII. McDonagh TA,Métra M,Adamo M,Gardner RS,Baumbach UN,Bohm M, et coll. Mise à jour ciblée 2023 des lignes directrices ESC 2021 pour le diagnostic et le traitement de l'insuffisance cardiaque aiguë et chronique.Eur Coeur J 2023;44:3627–39. https://doi.org/10.1093/eurheartj/ehad195 .Dans la presse.
XXXVIII. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy Ommen SR, Mital S, Burke MA, Day SM, Deswal A, Elliott P, Evanovich LL, Hung J, Joglar JA, Kantor P, Kimmelstiel C, Kittleson M, Link MS, Maron MS, Martinez MW, Miyake CY, Schaff HV, Semsarian C, Sorajja P.J Am Coll Cardiol. 2020 Dec 22;76(25):3022-55.
XXXIX. Rastegar N,Te Riele ASJM,James Californie,Bhonsale UN,Murray B,Tichnell C, et coll. Modifications fibrograisseuses : incidence à l'imagerie par résonance magnétique cardiaque chez les patients atteints de dysplasie/cardiomyopathie ventriculaire droite arythmogène.Radiologie 2016;280:405–12. https://doi.org/10.1148/radiol.2016150988.
XL. Rapezzi C,Aimo UN,Barison UN,Emdine M,Porcari UN,Linhart UN, et coll. Cardiomyopathie restrictive : définition et diagnostic.Eur Coeur J 2022;43:4679–93. https://doi.org/10.1093/eurheartj/ehac543.
XLI. Tini g,Sessarego E,Benenati S,Vianello PF,Musumeci B,Auteur C, et coll. Rendement du dépistage par scintigraphie osseuse de l'amylose cardiaque liée à la transthyrétine dans différentes conditions : enjeux méthodologiques et implications cliniques.Eur J Clin Invest 2021;51:e13665. https://doi.org/10.1111/eci.13665
XLII. Aimo UN,Merlo M,Porcari UN,Georgiopoulos g,Pagura L,Vergaro g, et coll. Redéfinir l’épidémiologie de l’amylose cardiaque. Une revue systématique et une méta-analyse des études de dépistage.Eur J Échec Cardiaque 2022;24:2342–51. https://doi.org/10.1002/ejhf.2532/.
XLIII. Global Burden of Disease Metrics. Institute for Health Metrics Evaluation. University of Washington, Seattle. Available at: https://vizhub.healthdata.org/gbd-compare/(accessed October 2021).
XLIV. Momtazmanesh S, Saeedi Moghaddam S, Malakan Rad E, Azadnajafabad S, Ebrahimi N, Mohammadi E, et al. Global, regional, and national burden and quality of care index of endocarditis: the global burden of disease study 1990–2019. Eur J Prev Cardiol 2022;29: 1287–97. https://doi.org/10.1093/eurjpc/zwab211.
XLV. Chirillo F, Scotton P, Rocco F, Rigoli R, Borsatto F, Pedrocco A, et al. Impact of a multidisciplinary management strategy on the outcome of patients with native valve infective endocarditis. Am J Cardiol 2013;112:. https://doi.org/10.1016/j.amjcard. 2013.05.060.
XLVI. Duval X, Millot S, Tubiana S, Prévention de l’endocardite infectieuse, La presse médicale , mai 2019, Pages 556-62.
XLVII. Alexis SL, Malik AH, George I, Hahn RT, Khalique OK, Seetharam K, et al. Infective endocarditis after surgical and transcatheter aortic valve replacement: a state of the art review. J Am Heart Assoc 2020;9:e017347. https://doi.org/10.1161/JAHA.120. 017347
XLVIII. Thornhill MH, Gibson T, Yoon F, Antibiotic Prophylaxis Against Infective Endocarditis Before Invasive Dental Procedures, JACC, sept 2022, 80(11):1029-41
XLIX. Casello S, Ajnone Marsan N, Fotboll E, Quintana E, 2023 ESC Guidelines for the Management of Endocarditis, ESC 2023, Présentation du 25 août 2023, Amsterdam, Pays-Bas.
L. Delgado V, Marsan Ajmone N, De Waha S, 2023 ESC Guidelines for the management of endocarditis: Developed by the task force on the management of endocarditis of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS) and the European Association of Nuclear Medicine (EANM), European Herat Journal, publication en ligne du 25 août 2023.
LI. Houpikian P, Raoult D. Blood culture-negative endocarditis in a reference center: etiologic diagnosis of 348 cases. Medicine (Baltimore) 2005. https://doi.org/10. 1097/01.md.0000165658.82869.17
LII. Li JS, Sexton DJ, Mick N, Nettles R, Fowler VG Jr, Ryan T, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis 2000;30: 633–38.
LIII. Marti-Carvajal AJ, Dayer M, Conterno LO, Gonzalez Garay AG, Marti-Amarista CE. A comparison of different antibiotic regimens for the treatment of infective endocarditis. Cochrane Database Syst Rev 2020;5:CD009880. https://doi.org/10.1002/14651858. CD009880.pub3.
LIV. Pries-heje M, Wiingaard C, Ihlemann N, Five-Year Outcomes of the Partial Oral Treatment of Endocarditis (POET) Trial, NEJM, fev 2022, 386(6):601-02.
LV. Iversen K, Ihlemann N, Gill S, Partial Oral versus Intravenous Antibiotic Treatment of Endocarditis, NEJM, janvier 2019.
LVI. Iung B, Doco-Lecompte T, Chocron S, Strady C, Delahaye F, Le Moing V, et al. Cardiac surgery during the acute phase of infective endocarditis: discrepancies between European Society of Cardiology guidelines and practices. Eur Heart J 2016; https://doi.org/10.1093/eurheartj/ehv65.
LVII. Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2022; 65:1925–66. https://doi.org/10.1007/ s00125-022-05787-2.
LVIII. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas:global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract 2022; 183:109119. https://doi. rg/10.1016/j.diabres.2021.109119.
LIX. WHO Guidelines Approved by the Guidelines Review Committee. Use of glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus: Abbreviated Report of a WHO Consultation. Geneva, Switzerland, 2011.
LX. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes
LXI. Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC). European Heart Journal (2023) 44, 4043–40. https://doi.org/10.1093/eurheartj/ehad192.
LXII. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int 2022;102(Suppl 5S):S1–S127. https://doi.org/10.1016/j.kint.2022.06.008.
LXIII. Fox CS, Matsushita K, Woodward M, Bilo HJ, Chalmers J, Heerspink HJL, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet 2012;380: 1662–73. https://doi.org/10.1016/S0140-6736(12)61350-6.
LXIV. SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J 2021;42:2439–54. https://doi.org/10.1093/eurheartj/ehab309 .
LXV. SCORE2-Diabetes Working Group and the ESC Cardiovascular Risk Collaboration. SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe. Eur Heart J 2023;44:2544–56. https://doi.org/10.1093/eurheartj/ehad260.
LXVI. SCORE2-OP working group and ESC Cardiovascular risk collaboration. SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. Eur Heart J 2021;42:2455–67. https://doi.org/10.1093/eurheartj/ehab312.
LXVII. Wood AM, Kaptoge S, Butterworth AS, Willeit P, Warnakula S, Bolton T, et al. Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies. Lancet 2018;391: 1513–23. https://doi.org/10.1016/S0140-6736(18)30134-X.
LXVIII. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298:1180–88. https://doi.org/10.1001/jama.298.10.1180.
LXIX. Zhou Y, Huang Y, Ji X, Wang X, Shen L, Wang Y. Pioglitazone for the primary and secondary Prevention of cardiovascular and renal outcomes in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis. J Clin Endocrinol Metab 2020;105:1670–81. https://doi.org/10.1210/clinem/dgz252.
LXX. de Jong M, van der Worp HB, van der Graaf Y, Visseren FL, Westerink J. Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials. Cardiovasc Diabetol 2017;16:134. https://doi.org/10. 1186/s12933-017-0617-4.
LXXI. Wang B, Zhong J, Lin H, Zhao Z, Yan Z, He H, et al. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. Diabetes Obes Metab 2013;15:737–49. https://doi.org/10.1111/dom.12085.
LXXII. Shah AD, Langenberg C, Rapsomaniki E, Denaxas S, Pujades-Rodriguez M, Gale CP, et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people. Lancet Diabetes Endocrinol 2015;3:105–13. https://doi.org/10.1016/S2213-8587(14)70219-0.
LXXIII. Mueller C, McDonald K, de Boer RA, Maisel A, Cleland JG, Kozhuharov N, et al. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. Eur J Heart Fail 2019;21:715–31. https:// doi.org/10.1002/ejhf.1494.
LXXIV. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed By the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2021;42:3599–26.https://doi.org/10.1093/eurheartj/ehab368.
LXXV. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020;383: 1413– 24. https://doi.org/10.1056/NEJMoa2022190.
LXXVI. Anker SD, Butler J, Filippatos G, Khan MS, Marx N, Lam CS, et al. Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status: results from the EMPEROR-reduced trial. Circulation 2021; 143: 337–49. https://doi.org/10.1161/CIRCULATIONAHA.120.051824.
LXXVII. Butler J, Anker SD, Filippatos G, Khan MS, Ferreira JP, Pocock SJ, et al. Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. Eur Heart J 2021; 42:1203– 12.https://doi.Dorg/10.1093/eurheartj/ehaa1007.